Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B2: alpelisib plus trastuzumab and pertuzumab maintenance for HER2-positive advanced breast cancer with PIK3CA mutation
MOH_2020-05-03_008901Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpelisib, trastuzumab and pertuzumab in breast cancer (5 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability for dose selection and Efficacy comparison of alpelisib versus placebo on trastuzumab and pertuzumab backbone. Started May 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2020-05-03_008901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-03_008901.